Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 239

1.

Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma.

Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakamura H, Nakashima A, Sueda T.

Ann Surg. 2009 Dec;250(6):950-6.

PMID:
19953713
2.

Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: outcomes and prognostic factors.

Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Sakabe R, Kobayashi H, Kondo N, Nakagawa N, Sueda T.

J Hepatobiliary Pancreat Sci. 2012 Jul;19(4):306-13. doi: 10.1007/s00534-011-0498-y.

PMID:
22270151
3.

Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas.

Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Ohge H, Sueda T.

J Gastrointest Surg. 2009 Jan;13(1):85-92. doi: 10.1007/s11605-008-0650-4. Epub 2008 Aug 13.

PMID:
18704593
4.

Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma.

Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Kondo N, Nakagawa N, Sueda T.

J Surg Oncol. 2012 Aug 1;106(2):174-80. doi: 10.1002/jso.23068. Epub 2012 Feb 13.

PMID:
22331838
5.

Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma.

Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakamura H, Nakashima A, Sueda T.

J Gastrointest Surg. 2009 Aug;13(8):1470-9. doi: 10.1007/s11605-009-0900-0. Epub 2009 May 7.

PMID:
19421824
6.

Surgical treatment and adjuvant chemotherapy for patients with biliary tract cancer: single institution experience of 100 patients.

Harada N, Shirabe K, Yoshizumi T, Ikegami T, Uchiyama H, Soejima Y, Yamashita Y, Saeki H, Oki E, Kawanaka H, Morita M, Ikeda T, Matsuura H, Okadome K, Maehara Y.

Fukuoka Igaku Zasshi. 2013 Dec;104(12):539-48.

PMID:
24693682
7.

Prognostic factors of patients with advanced gallbladder carcinoma following aggressive surgical resection.

Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Kondo N, Sakabe R, Kobayashi H, Sueda T.

J Gastrointest Surg. 2011 Jun;15(6):1007-16. doi: 10.1007/s11605-011-1479-9. Epub 2011 Mar 10.

PMID:
21547707
8.

A retrospective study of S-1 monotherapy as second-line treatment for patients with advanced biliary tract cancer.

Kobayashi S, Ueno M, Ohkawa S, Andou T, Kameda R, Yamamoto N, Morinaga S.

Jpn J Clin Oncol. 2012 Sep;42(9):800-6. doi: 10.1093/jjco/hys102. Epub 2012 Jul 23.

PMID:
22826349
9.

A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in curatively resected patients with biliary tract cancer: adjusting the dose of adjuvant chemotherapy according to the surgical procedures.

Takahara T, Nitta H, Hasegawa Y, Itou N, Takahashi M, Nishizuka S, Wakabayashi G.

Cancer Chemother Pharmacol. 2012 May;69(5):1127-33. doi: 10.1007/s00280-011-1805-7. Epub 2011 Dec 30.

PMID:
22207029
10.

Randomized phase II study of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805).

Takashima A, Morizane C, Ishii H, Nakamura K, Fukuda H, Okusaka T, Furuse J.

Jpn J Clin Oncol. 2010 Dec;40(12):1189-91. doi: 10.1093/jjco/hyq110. Epub 2010 Jul 14.

PMID:
20630899
11.

Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma.

Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakagawa N, Ohge H, Sueda T.

Am J Surg. 2008 Jun;195(6):757-62. doi: 10.1016/j.amjsurg.2007.04.018.

PMID:
18367131
12.

A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer.

Suzuki E, Ikeda M, Okusaka T, Nakamori S, Ohkawa S, Nagakawa T, Boku N, Yanagimoto H, Sato T, Furuse J.

Cancer Chemother Pharmacol. 2013 May;71(5):1141-6. doi: 10.1007/s00280-013-2106-0. Epub 2013 Mar 24.

13.

Early initiation of adjuvant chemotherapy improves survival of patients with pancreatic carcinoma after surgical resection.

Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Nakagawa N, Sasaki H, Sueda T.

Cancer Chemother Pharmacol. 2013 Feb;71(2):419-29. doi: 10.1007/s00280-012-2029-1. Epub 2012 Nov 21.

PMID:
23178955
14.

A single-center analysis of the survival benefits of adjuvant gemcitabine chemotherapy for biliary tract cancer.

Yamanaka K, Hatano E, Kanai M, Tanaka S, Yamamoto K, Narita M, Nagata H, Ishii T, Machimoto T, Taura K, Uemoto S.

Int J Clin Oncol. 2014;19(3):485-9. doi: 10.1007/s10147-013-0578-x. Epub 2013 Jun 14.

PMID:
23765238
15.

S-1 vs. gemcitabine as an adjuvant therapy after surgical resection for ductal adenocarcinoma of the pancreas.

Okabayashi T, Shima Y, Iwata J, Morita S, Sumiyoshi T, Kozuki A, Tokumaru T, Iiyama T, Kosaki T, Kobayashi M, Hanazaki K.

World J Surg. 2014 Nov;38(11):2986-93. doi: 10.1007/s00268-014-2703-z.

PMID:
25104544
16.

[Effect of pylorus-preserving pancreaticoduodenectomy on serum levels of 5-fluorouracil during S-1 treatment for pancreaticobiliary malignancy].

Muneoka K, Shirai Y, Sasaki M, Wakai T, Sakata J, Kanda J, Wakabayashi H, Hatakeyama K.

Gan To Kagaku Ryoho. 2010 Aug;37(8):1503-6. Japanese.

PMID:
20716875
17.

A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer.

Sasaki T, Isayama H, Nakai Y, Ito Y, Yasuda I, Toda N, Kogure H, Hanada K, Maguchi H, Sasahira N, Kamada H, Mukai T, Okabe Y, Hasebe O, Maetani I, Koike K.

Cancer Chemother Pharmacol. 2013 Apr;71(4):973-9. doi: 10.1007/s00280-013-2090-4. Epub 2013 Jan 26.

PMID:
23355041
18.

An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer.

Katayose Y, Ohtsuka H, Kitamura Y, Masuda K, Nakagawa K, Yamamoto K, Yoshida H, Onogawa T, Motoi F, Naitoh T, Rikiyama T, Egawa S, Unno M.

Hepatogastroenterology. 2012 May;59(115):691-5. doi: 10.5754/hge11530.

PMID:
22469710
19.

Lymphatic invasion is an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with gemcitabine or S-1.

Aoyama T, Murakawa M, Katayama Y, Shiozawa M, Ueno M, Morimoto M, Yoshikawa T, Rino Y, Masuda M, Morinaga S.

Hepatogastroenterology. 2015 Mar-Apr;62(138):472-7.

PMID:
25916085
20.

Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer.

Uwagawa T, Sakamoto T, Abe K, Okui N, Hata D, Shiba H, Futagawa Y, Aiba K, Yanaga K.

Cancer Chemother Pharmacol. 2015 Jan;75(1):191-6. doi: 10.1007/s00280-014-2636-0. Epub 2014 Nov 25.

PMID:
25422155

Supplemental Content

Support Center